Love Is Blind Season 10 Weddings: Who Bought Married?

Clay Gravesande and AD Smith: Broke up

While Clay expressed his reservations about marriage due to his own judgment of his father’s infidelity, AD assured him that they would make it as a couple and that everything seemed fine between the two.

But when faced with the task of saying at the altar I will forever, Clay instead said I won’t, telling AD that it wouldn’t be “responsible” for him to get married even though he knew he wasn’t ready.

Announce the shock.

“I’m going to put in the work for you,” he told AD, “and we’re going to get through this together. I don’t care what no one says; I know for a fact that I’m not ready for marriage and you deserve the best. And if I’m not ready to give you 100 percent, I won’t go there with you if I’m not ready… I can’t say yes now.”

It was a revelation that led AD to tearfully declare that the relationship was a waste of her “fucking time.”

As for Clay, he also revealed that financial – and emotional – ties played a big role in him leaving. “I looked at myself in the mirror and said, ‘Am I a husband?'” he admitted, “and the answer was no. Am I deeply in love? The answer was no.”

During the reunion, Clay expressed that he made a mistake and wanted to date AD, but she remained reticent about ever thinking about getting back together.

AD confessed that she went on a few dates with her co-star Matthew Duliba packed up after filming, but they are not together.

In May 2025, she announced that she was expecting her first child with her fiancé Ollie Sutherland.

We have been lively in buying and selling in the course of the aftermath of the Iran Struggle. Jim Cramer explains our method

Spanish Prime Minister Sánchez rejects Trump’s risk to cease all commerce

President of the Government Pedro Sanchez speaks during the official opening dinner of the Mobile World Congress (MWC) Barcelona 2026 at the Museu Nacional d’Art de Catalunya on March 1, 2026 in Barcelona, ​​Catalonia, Spain.

Europe Press News | Europa Press | Getty Images

Spanish Prime Minister Pedro Sánchez stepped up his criticism of US attacks against Iran on Wednesday, describing the escalating Middle East conflict as a “catastrophe”.

His comments came after US President Donald Trump vowed to halt trade with Madrid after the Spanish government blocked the use of two jointly operated bases on its territory for the attacks.

“Spain was terrible,” Trump said Tuesday during a press conference at the White House alongside Chancellor Friedrich Merz. “We will cut off all trade with Spain. We want nothing to do with Spain,” he added.

In a televised address Wednesday morning, Sánchez said: “Great wars very often begin with a chain of events that spin out of control due to miscalculations, technical failures and unforeseen circumstances. That is why we must learn from history and cannot play Russian roulette with the fate of millions of people,” a CNBC translation said.

Sánchez warned against “repeating the mistakes of the past,” drew a comparison with the invasion of Iraq in the early 2000s and summarized the government’s position as “no to war.”

Spain’s socialist prime minister has become one of the leading critics of US and Israeli attacks against Iran among EU leaders.

Trump’s latest comments follow his condemnation of Madrid’s refusal to meet NATO’s defense spending target of 5% of GDP.

of Spain Capricorn 35 The index was trading 1.4% higher around 10:17 a.m. London time (5:17 a.m. ET), recouping earlier losses on jittery U.S. trading. Meanwhile, the pan-European Stoxx 600 index rose by around 1.2%.

Trump’s threat to punish Spain on trade would be a challenge given that the 27 EU states negotiate trade deals together.

“It is naive to believe that democracy or respect between nations can arise from ruins, or to believe that blind and submissive obedience is a form of leadership. On the contrary, I believe this position is leadership,” Sánchez said.

“We will not be complicit in something that is bad for the world and contrary to our values ​​and interests, just for fear of reprisals from others,” he added.

—CNBC’s Charlotte Reed contributed to this report.

After the assaults in Iran, Democrats are cautious about impeaching Trump

Representative Al Green shouts as President Donald Trump addresses a joint session of Congress at the U.S. Capitol in Washington, DC on March 4, 2025.

Win Mcnamee | Via Reuters

Since the U.S. attack on Iran, Democrats in Congress and opponents of President Donald Trump have called the operation unconstitutional and vowed to rein in the president. But further impeachment – which the president fears if Democrats retake the US House of Representatives – has not entered serious discussion.

That could change after the midterm elections if the party wins the House of Representatives and Republicans lose their control of both chambers of Congress and the White House. Knowing he would be in Democrats’ crosshairs, Trump has expressed fear of a third impeachment trial to Republicans in Congress, telling them they must win in November.

“If you’re going to attack him, you want to make sure you don’t miss him,” Jared Leopold, a Democratic strategist who has worked on the Hill and for the Democratic Senate Campaign Committee, said in an interview.

House Democrats met last week to hammer out strategy for this year. They met before the new Iran war – which Trump started without seeking congressional approval – provided another possible reason for impeachment.

Impeachment tends to be unpopular with voters, and there is concern in some parts of the Democratic establishment that previous attempts to rein in Trump have failed to gain traction. He was impeached by the U.S. House of Representatives in 2019 over allegations that he withheld military aid to Ukraine to exert political pressure, and in 2021 over his actions leading up to the riots at the U.S. Capitol on January 6, 2020. Both times the Senate voted to acquit.

But if Democrats win back the House, there will likely be serious pressure to impeach Trump a third time. No other president has been impeached twice.

“We are not afraid of impeachment or any other constitutional tool in our arsenal, but we have learned that impeachment is not a panacea,” Rep. Jamie Raskin, D-Md., the top Democrat on the House Judiciary Committee, said in an interview before the Iran operation.

“For us it’s not a fetish, but for us it’s not taboo either,” Raskin said. “If we believe this is the most effective way to address some of the crises facing the Republic that have been unleashed by President Trump or certain members of his Cabinet, then we need to think about it.”

Read more about CNBC’s politics coverage

Given that any talk of impeachment is purely symbolic and Republicans control both the House and Senate, Leopold said he doesn’t expect there to be an uptick in impeachment talk in the near term.

“You saw some come out in different places and usually use the ‘I word’ as some kind of attention-grabbing tool,” Leopold said. “More than anything, people want Democrats to push back in a way that has real-world impact.

While the attack on Iran did not prompt a flood of new calls for impeachment, Democrats have threatened to impeach Trump since Trump took office last year over his attacks on Iran in 2025, his overthrow of Venezuelan President Nicolas Maduro without congressional approval and a range of other alleged crimes.

Rep. Maxine Waters of California, who said before Maduro’s ouster in January that she would “reconsider” her view that it was now unrealistic to seek impeachment, is now rejecting any similar effort.

“I don’t want to go there. I think we’re focused on what’s happening in Iran,” Waters said Tuesday as she left a Trump administration briefing on the Iran operation. “I think when we take control of the House, we’ll think about it.”

“High Crimes and Crimes”

Calls for impeachment have emerged on the campaign trail in recent days, potentially foreshadowing what could be a contentious issue for Democrats in 2027.

In a crowded Democratic primary for the open seat in Illinois’ 9th Congressional District, three candidates demanded that Congress impeach and remove Trump.

“The morally bankrupt Trump administration teamed up with another morally bankrupt authoritarian to declare an unprovoked war on Iran that has already killed scores of civilians,” candidate Kat Abughazaleh posted on BlueSky. “We need an immediate vote in Congress on a War Powers Resolution. Then impeachment.”

Fellow candidates Evanston, Illinois Mayor Daniel K. Biss and state Sen. Laura Fine also called for Trump’s impeachment.

Before the attack on Iran, Democratic leaders considered how they could effectively rein in Trump without drowning out other issues. Party leaders have talked about prioritizing an affordability message, the same issue Republicans want Trump to focus on in the election year.

When Texas Rep. Al Green introduced a resolution to impeach Trump in December, only 140 Democrats voted against a motion to table the measure. House Minority Leader Hakeem Jeffries, whose leadership team chose not to seek votes for the resolution, was one of 47 Democrats who voted “present” and neither supported nor opposed the measure.

“What we tell our members and candidates who are running is that we have to do everything,” Democratic Caucus Chairman Pete Aguilar, D-California, said at the Democratic political retreat last week. “We need to provide oversight and accountability and talk about the affordability agenda and how we can improve people’s lives when we are given the opportunity to lead and when we are given the opportunity to govern.”

Rep. Deborah Ross, D-N.C., a member of the House Judiciary Committee, said at the retreat that a Democratic attempt at impeachment was all but certain. The problem, she said, will be figuring out on what grounds to impeach. Jeffries “won’t just be a freebie for everyone,” she said.

“I think the difficulty would be narrowing down the number of felonies and misdemeanors. Because I think there are a lot of felonies and misdemeanors,” Ross said.

A $Three trillion alternative for Black entrepreneurs is rising

Black and other minority entrepreneurs have a $3 trillion opportunity to become entrepreneurs through the Great Business Transfer, according to a new report from McKinsey.

“This is the largest ownership transfer in modern U.S. history,” said report co-author Shelley Stewart, senior partner and chair of the McKinsey Institute for Economic Mobility. “This is a great opportunity, but there is also a challenge. The problem is that many viable businesses may not be successfully transferred because the market to connect buyers, sellers and capital is not built at scale.”

Researchers predict that 6 million small and medium-sized enterprises (SMEs) will be available for acquisition by 2035. If Black, Latino and women entrepreneurs can increase their stakes in these transforming companies, there is the potential to unlock $3 trillion in new household wealth, the report says.

McKinsey said the contrast between opportunity and risk is particularly stark for the black community.

Only 3% of U.S. entrepreneurs are Black, compared to 13% of the population. If current trends continue, Black entrepreneurs are expected to gain $87 billion in transferred business value. However, if they increase their participation in the Great Business Transfer, the figure could rise to over $369 billion. Conversely, without greater participation, wealth disparities would only widen, the report says.

Stewart added that the impact of transmission extends far beyond underrepresented communities.

“Success is achieved by having the broadest possible pool of entrepreneurs who can buy these companies. So that means you have to be inclusive,” Stewart said. “This is in the interest of all Americans. This impacts employment, it impacts local economic spending, it impacts wealth creation.”

Financing and business discovery

According to McKinsey, the biggest challenges for potential buyers in Black and other minority communities will be financing, accessing deal flow and navigating the advisory process in an acquisition.

“We have more Black check writers at venture capital firms and buyout firms than ever before,” said Jacob Walthour of Blueprint Capital Advisors. “We also work in other traditional financial institutions like banks, so the capital is there.”

But Walthour added that it is imperative for members of the Black and minority communities to understand the dynamics of acquiring a business versus starting a new business.

“You can get people to put capital into a business that already exists. One of the hardest things is raising capital to build that business,” Walthour said. “The basic principles of capitalism should always be in place, and that includes return on capital. This is how professional investors think about capital allocation.”

John Hope Bryant, founder and CEO of Operation Hope, also emphasized the need for Black entrepreneurs to seek opportunities in key industries rather than personal interests.

“You don’t have to fall in love with this business,” Bryant said. “Business is not personal. Once that change happens and you combine the hustle we have with the untapped ambition, you become a millionaire. We’ve never tried this boring, traditional approach.”

The planning process

The McKinsey report highlights five phases of a successful ownership transition: aspiration and preparation, search and sourcing, deal structuring and financing, ownership and value creation, and succession and exit.

Sheena Gray, CEO of the African American Advisors Association, said the transfer underscores the need for certified financial planners as, in many cases, potential buyers would be entering uncharted financial territory.

“The right planning infrastructure can be useful for expanding minority ownership in companies,” Gray said. “Certified financial planners are better able to structure tax strategies that will help someone when they want to strategically transition into ownership. It’s an important component that most business owners don’t think about when they talk about acquiring a new opportunity.”

Brandon William Jones, founder of Gravy Wealth, works with the National Black MBA Association to help professionals become entrepreneurs, a transition he calls from “earner” to “owner.”

“It’s more important now than ever to stay in control and capture the value you create,” Jones said. “The world is moving to a place where workers, especially knowledge workers, are now becoming optional.”

You have influence

McKinsey’s Stewart said the potential for disruption from AI only increases the potential for corporate acquisitions.

“What’s in the 6 million businesses? There’s retail, there’s restaurants, there’s construction, there’s healthcare. There’s small manufacturing businesses. Those will certainly be impacted by AI, but these are labor-intensive businesses that continue to need workers,” Stewart said. “AI will play a role in helping entrepreneurs become smart across various industries. AI is unlikely to make these companies obsolete.”

“It’s going to be a question of whether we can create the market mechanism that connects companies to entrepreneurs and capital. I actually think we could see an acceleration in the next decade if we can bring together the infrastructure that actually gets people to buy these companies.”

Jones also said that AI can also be an important tool for reducing wealth and ownership disparities: “If someone advances AI, not only can they potentially acquire that company, but they can also implement the AI ​​playbook to drive much more efficiency and value.”

Why Multifamily Properties Are a Smart Play for Real Estate Investors in 2026

Picture this: a bustling apartment complex filled with tenants who reliably pay rent every month. The building stands strong through economic ups and downs, offering steady cash flow and long-term appreciation. This isn’t just a dream scenario-it’s the reality many real estate investors are chasing in 2026 by focusing on multifamily properties.

With shifting demographics, evolving market dynamics, and changing tenant preferences, multifamily real estate is carving out a unique niche as a resilient and lucrative investment. Here’s why this multifamily property real estate investing deserves serious attention this year.

Rising Demand for Rental Housing

One of the biggest drivers behind the multifamily boom is the surging demand for rental units. Homeownership rates have dipped slightly in recent years, partly due to affordability challenges and lifestyle preferences. Younger generations, especially Millennials and Gen Z, are renting longer and prioritizing flexibility over owning a home.

According to recent data from the U.S. Census Bureau, the national homeownership rate hovered around 65% in early 2026, down from a peak near 69% a decade ago. Meanwhile, rental vacancy rates remain low, often below 5% in many urban and suburban markets. This tight supply-demand balance pushes rents upward, benefiting multifamily landlords.

Additionally, the rise of remote work has expanded the geographic appeal of rental properties. People are no longer tethered to city centers and are seeking multifamily communities in suburban and secondary markets. This trend widens the pool of potential tenants and creates new opportunities for investors willing to look beyond traditional hotspots.

Demographic Shifts Fueling Growth

Baby Boomers downsizing, young professionals delaying home purchases, and immigrants settling in urban areas all contribute to the growing renter population. The U.S. Census projects that by 2030, over 60% of households will rent at least once in their lifetime, underscoring the long-term nature of this trend.

Multifamily properties cater well to these groups by offering amenities, convenience, and community. Investors who understand these demographic nuances can better position their portfolios for sustained demand.

Furthermore, the increasing popularity of urban living among younger generations has led to a surge in demand for rental units that provide not just a place to live, but a lifestyle. Many multifamily developments now feature co-working spaces, fitness centers, and social lounges, creating environments that foster community interaction and cater to the needs of a diverse tenant base. This shift towards lifestyle-oriented living is particularly appealing to Millennials and Gen Z, who often prioritize experiences and social connectivity over traditional markers of success like homeownership.

Moreover, the influx of technology and innovation into the rental market has transformed how properties are managed and marketed. Smart home features, eco-friendly building practices, and enhanced digital communication channels are becoming standard expectations for renters. As these technological advancements continue to evolve, they not only improve the living experience but also increase operational efficiencies for property managers, making multifamily investments even more attractive in a competitive landscape.

Economies of Scale and Operational Efficiency

Managing a single-family rental is one thing; handling dozens or hundreds of units under one roof is another. Multifamily properties offer significant economies of scale that can improve profitability and reduce headaches.

For starters, maintenance and management costs per unit tend to be lower in multifamily buildings. Instead of dispatching a contractor to multiple scattered houses, repairs can be centralized. Property management teams can operate more efficiently, and bulk purchasing of supplies reduces expenses. This centralized approach not only streamlines operations but also fosters stronger relationships with service providers, who may offer better rates or priority service due to the volume of business.

This efficiency translates into higher net operating income (NOI) and better margins. It also makes it easier to implement upgrades or retrofit buildings with energy-saving technologies, which tenants increasingly value. Additionally, the ability to implement uniform policies and procedures across all units can enhance tenant satisfaction, as residents enjoy consistent service and amenities, contributing to higher retention rates.

Mitigating Vacancy Risks

Vacancy risk is a major concern for any landlord. With single-family homes, a vacant property means zero income until a new tenant moves in. Multifamily properties spread that risk across multiple units. If one apartment sits empty, the rest still generate cash flow, cushioning the impact.

This diversification within a single asset makes multifamily investments more resilient during economic downturns or local market fluctuations. Investors can weather short-term vacancies without jeopardizing their overall financial health. Moreover, multifamily properties often attract a diverse tenant base, from young professionals to families, which can further stabilize occupancy rates. The ability to adapt marketing strategies to target various demographics allows property managers to fill vacancies more quickly, ensuring a steady stream of income even in challenging market conditions.

Attractive Financing and Investment Structures

Financing multifamily properties has become more accessible and favorable in 2026. Lenders recognize the stability of this asset class and often offer competitive interest rates and longer amortization periods compared to other commercial real estate sectors.

Government-backed programs, like those from Fannie Mae and Freddie Mac, provide attractive loan options for multifamily investors, especially for properties with five or more units. These programs often feature lower down payments and flexible underwriting standards.

Moreover, multifamily assets fit well into various investment structures-from individual ownership to syndications and real estate investment trusts (REITs). This flexibility allows investors with different risk tolerances and capital levels to participate.

Leveraging Technology and Data Analytics

Technology is transforming how multifamily properties are bought, managed, and optimized. Advanced data analytics help investors identify emerging markets, forecast rent growth, and assess property performance with greater precision.

Property management software streamlines tenant communications, rent collection, and maintenance requests, improving tenant satisfaction and retention. Smart home devices and energy management systems reduce operating costs and appeal to tech-savvy renters.

Investors who embrace these tools gain a competitive edge by maximizing operational efficiency and enhancing the tenant experience.

Resilience in Uncertain Economic Times

Economic uncertainty often shakes investor confidence, but multifamily properties have historically proven to be a safe harbor. During recessions, rental demand tends to rise as fewer people can afford to buy homes. This counter-cyclical nature makes multifamily real estate investing a valuable portfolio diversifier.

The 2020 pandemic underscored this resilience. While many commercial real estate sectors struggled, multifamily housing remained relatively stable. Rent collections dipped briefly but rebounded quickly, supported by government stimulus and tenant demand.

Looking ahead, inflation concerns and rising interest rates make fixed-income investments less attractive. Multifamily properties, with their potential for rent increases tied to inflation, offer a hedge against eroding purchasing power.

Long-Term Appreciation Potential

Beyond cash flow, multifamily properties can appreciate significantly over time. Urbanization trends, infrastructure investments, and demographic shifts support steady property value growth in many markets.

Investors who acquire well-located properties and maintain them effectively can benefit from capital appreciation alongside rental income. Strategic renovations and repositioning can unlock additional value, turning older buildings into highly sought-after communities.

Challenges to Consider

No investment is without risks. Multifamily properties require active management and can involve complex regulatory environments, especially in rent-controlled cities. Property taxes, insurance, and maintenance costs can fluctuate, impacting profitability.

Competition for quality assets is intense, driving prices up in some markets. Investors must conduct thorough due diligence, including market analysis, financial modeling, and property inspections, to avoid overpaying or underestimating expenses.

Tenant turnover and compliance with fair housing laws also demand attention. Building strong relationships with tenants and maintaining transparent communication helps reduce vacancies and legal issues.

Final Thoughts

Multifamily real estate stands out in 2026 as a compelling investment choice. The combination of strong rental demand, operational efficiencies, favorable financing, and economic resilience creates a powerful value proposition.

Investors who approach this sector with careful research, strategic planning, and a willingness to leverage technology are well-positioned to capitalize on its advantages. Whether seeking steady income, portfolio diversification, or long-term growth, multifamily properties offer a smart path forward in today’s complex real estate landscape.

Metformin for Longevity: Understanding Its Anti-Aging Potential

Metformin has been used for decades. Not as a wellness trend. Not as a supplement experiment. As a prescription drug with a long safety record in metabolic disease. What has changed is how researchers now view the drug. Instead of asking only how Metformin lowers blood glucose, the question has widened. Can Metformin support longevity? And if so, how?

This article focuses on Metformin and healthy aging. Not hype. Not promises. Just what the evidence shows so far, why researchers keep paying attention, and where people often misunderstand what Metformin can and cannot do when used for long-term health goals.

Why Metformin Entered the Longevity Conversation

Longevity research often starts in unexpected places. In this case, it started with population data. Large observational studies noticed something unusual. People with type 2 diabetes taking Metformin often lived as long as, or longer than, people without diabetes. That outcome runs against expectations. Diabetes typically shortens lifespan. Yet in multiple datasets, Metformin users showed lower all-cause mortality than comparable groups using other metabolic therapies.

That observation didn’t prove causation. But it was strong enough to raise questions.

From there, researchers began studying Metformin beyond glucose control. Vascular health     . Inflammation markers. Cellular senescence     . Mitochondrial stress responses. These pathways matter not just for diabetes, but for aging itself.

Metformin for longevity entered serious scientific discussion because it touched many of the same biological processes that accelerate aging.

How Metformin Interacts with Aging Pathways

Aging is not one process. It is a collection of slow, cumulative changes that affect cells, tissues, and systems. Metformin appears to influence several of those areas at once.

One major mechanism involves insulin sensitivity. Chronically high insulin levels are linked to metabolic dysfunction, cardiovascular disease, and faster biological aging. Metformin improves insulin sensitivity, which lowers circulating insulin demand over time. That matters for long-term metabolic stability.

Another area involves cellular stress response systems. Metformin activates AMPK, an enzyme that helps cells respond to low-energy states, like fasting. AMPK activation is associated with improved cellular repair processes and enhanced mitochondrial function     . That balance becomes more important with age.

Inflammation also plays a role. Low-grade chronic inflammation increases as people age. This process, sometimes called inflammaging, contributes to cardiovascular disease, neurodegeneration, and metabolic decline. Metformin has been shown to reduce inflammatory signaling in multiple studies.

None of this means Metformin stops aging. But it may slow specific processes that drive age-related disease.

Metformin Anti-Aging Research: What the Evidence Actually Shows

Much of the strongest evidence comes from observational studies and animal models. In rodents, Metformin has extended lifespan under certain conditions. In humans, large population studies show reduced risk of cardiovascular events, lower cancer incidence     , and reduced mortality      compared to other glucose-lowering drugs.

The most discussed human study in this space is the proposed TAME trial, short for Targeting Aging with Metformin. The goal is not to prove immortality. The goal is to test whether Metformin can delay the onset of multiple age-related diseases at once. That includes heart disease, cancer, cognitive decline, and mortality.

This approach matters. Aging research has shifted away from treating one disease at a time. Instead, researchers are testing whether slowing underlying aging biology reduces multiple conditions together. Metformin fits that framework better than many newer drugs because of its long clinical history.

Metformin anti-aging research continues to grow because it is testable, measurable, and grounded in known biology.

Metformin and Cardiovascular Aging

Cardiovascular disease remains the leading cause of death worldwide. Aging increases arterial stiffness, endothelial dysfunction, and plaque formation. Metformin has shown benefits in several of these areas.

Studies have linked Metformin use to reduced risk of heart attack      and stroke in people with metabolic disease. Some data suggests benefits extend beyond glucose control alone. Improved lipid profiles. Reduced oxidative stress. Better endothelial function.

These effects matter for longevity because cardiovascular health sets the ceiling for lifespan in many individuals. Even modest reductions in cardiovascular risk compound over decades.

Metabolic Health as a Longevity Foundation

Longevity discussions often drift into abstract territory. But metabolic health remains central. Blood sugar regulation, insulin sensitivity, and cellular energy balance shape how the body ages.

Metformin improves metabolic efficiency. It reduces hepatic glucose production. It improves peripheral glucose uptake. It lowers insulin demand. Over time, those changes reduce metabolic strain.

For individuals focused on healthy aging, metabolic stability is not optional. It is foundational. Metformin for longevity is not about chasing youth. It is about reducing long-term metabolic damage that accelerates aging.

Common Misunderstandings About Metformin for Longevity

One mistake is thinking Metformin works the same way for everyone. Dose matters. Timing matters. Baseline metabolic health matters. Using too much or using it without medical guidance increases risk without added benefit.

Another mistake is assuming Metformin replaces lifestyle choices. Nutrition, physical activity, sleep, and stress management still dominate outcomes. Metformin works alongside those factors, not instead of them.

Some people also assume any Metformin source is equivalent. That assumption can cause real problems, especially when quality control and dosing oversight are missing.

The Longevity Conversation

As interest in Metformin for longevity grows, sourcing becomes critical. Prescription medications require precision. Not just in formulation, but in dosing, monitoring, and ongoing evaluation.

AgelessRx operates at that intersection. The platform focuses on longevity therapies while maintaining medical oversight. For Metformin, that means prescriptions are based on real clinical evaluation. Dosages are selected intentionally and tailored towards an individual’s goals. Patients are monitored by medical staff over time.

That structure matters. Longevity-focused use is different from short-term treatment. Long-term outcomes depend on consistency, authenticity of the medication, and appropriate dosing adjustments as needed over time. AgelessRx provides assurance that the product is real, regulated, and supported by clinicians who understand how Metformin fits into a broader healthy aging strategy.

Metformin is emerging as a potential anti-aging therapy partly because platforms like AgelessRx allow it to be used responsibly, with oversight, rather than as an unregulated experiment.

Where the Research Is Headed

Metformin remains one of the most studied drugs in aging research because it is affordable, widely available, safe and broadly effective     . Future studies will likely refine who benefits most, what dosing strategies work best, and how Metformin interacts with other longevity-focused therapies.

The question is no longer whether Metformin influences longevity     . The question is how to apply it with precision for maximum benefit     .

Can Metformin Support Longevity?

The evidence suggests Metformin supports healthier aging in specific ways. Improved metabolic control. Reduced inflammation. Better cardiovascular outcomes. Possible protection against a cluster of age-related diseases.      

Metformin for longevity is not a shortcut. It is a tool. One backed by decades of clinical use and a growing body of aging research. When used appropriately, with medical oversight, it fits into a realistic, evidence-based approach to extending healthspan.

Healthy aging does not come from one intervention. But Metformin continues to earn attention because it addresses core drivers of aging rather than surface symptoms.

That is why researchers keep studying it. And why interest continues to grow.

Ashton Kutcher returns to appearing in The Magnificence

Ashton Kutcher does not bother anyone with this beauty treatment.

At least the company doesn’t. After all, it is That 70s show Alum returned to acting after a three-year hiatus and starred in Ryan Murphyis the upcoming series The beauty, transforming ordinary people into works of art.

“I’m the world’s biggest damn advertisement for the hottest new super drug that will make you effortlessly beautiful,” Ashton’s character, simply called “The Corporation,” announced in the Jan. 5 trailer. “A simple injection to become a beauty.”

The intended effects can also be relayed in unconventional ways in the FX show, premiering Jan. 21 on Hulu. As the tech billionaire revealed, “It’s a sexually transmitted disease that people actually want.”

Unfortunately the injection appears have some unforeseen consequences and turn into a virus that leads to gruesome side effects and the gruesome death of supermodels. In fact, Bella Hadid‘s Ruby seems unable to contain her anger in a restaurant kitchen as she attacks chefs her Face Is burnt and blistered.

First GLP-1 anti-obesity capsule from Novo Nordisk launches within the US

The logo of pharmaceutical company Novo Nordisk is seen outside its offices in Bagsvaerd on the outskirts of Copenhagen on November 24, 2025.

Tom Little | Reuters

Novo Nordisk will begin rolling out the first-ever GLP-1 weight loss pill in the United States on Monday, the company announced, marking a new chapter in obesity treatment in the United States

The drug’s cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. That raises hopes that pills could help overcome the long-standing affordability hurdles associated with the weekly injections that dominate the weight-loss drug market.

The official launch of the oral drug, the Wegovy pill, comes just two weeks after US regulators approved the treatment.

The starting dose of 1.5 milligrams is available at more than 70,000 U.S. pharmacies, such as: CVS And Costcoas well as select telemedicine providers including Ro, LifeMD, Weight WatchersGoodRx and Novo Nordisk’s NovoCare Pharmacy. The higher, remaining doses of the pill will be available to patients by the end of the week, Novo Nordisk said.

Cash-paying patients can pay $149 per month for the initial dose. The 4-milligram dose of the pill will also be available for $149 per month until April 15, and $199 per month thereafter.

The highest doses of the Wegovy pill – 9 milligrams and 25 milligrams – will be available for $299 per month. Patients with insurance coverage for the drug can pay as little as $25 per month for treatment.

Patients who pay cash can also access initial doses of the pill for $149 a month on President Donald Trump’s direct-to-consumer website, TrumpRx, under an agreement Novo Nordisk struck with its government in November. The website will also launch in January, although it is unclear when.

Novo Nordisk said Monday that the availability of the pill “opens up new possibilities” for the more than 100 million Americans living with obesity.

Injections from Novo Nordisk and its main competitor Eli Lillyhave a list price of about $1,000 per month. However, both companies are offering lower cash prices for their vaccinations, ranging from $299 to $499 per month depending on the dose.

Pills are the next battleground for the two companies that founded the booming GLP-1 sector, which some analysts believe could be worth about $100 billion by the 2030s. Analysts at Goldman Sachs said in August that oral drugs could capture a 24% share – or about $22 billion – of the global weight-loss drug market in 2030.

Novo Nordisk’s daily oral drug launch on Monday gives the company a clear lead. The Food and Drug Administration approved the treatment on Dec. 22 and will decide later this year whether to withdraw a rival pill from Eli Lilly.

More CNBC Health coverage

The FDA also approved Novo Nordisk’s pill to reduce the risk of serious cardiovascular events, such as death, heart attack or stroke, in adults with obesity and existing cardiovascular disease.

This is in line with the approval of the company’s blockbuster weight loss drug Wegovy, which contains the same active ingredient semaglutide. Both work by mimicking the gut hormone GLP-1 to suppress appetite.

“This moment is about transforming the possibilities of weight management, and to make this possible we have worked to ensure this.” [the Wegovy pill] is affordable and accessible to those who need it, regardless of how they choose to receive care,” said Ed Cinca, senior vice president of marketing and patient solutions at Novo Nordisk, in a press release.

People taking the Novo Nordisk pill must wait 30 minutes each day before eating or drinking.

In a Phase III trial that followed more than 300 adults with obesity rather than diabetes, Novo Nordisk’s highest dose of oral semaglutide helped patients lose an average of up to 16.6% of their weight after 64 weeks. That weight loss was 13.6% when the company analyzed all patients, regardless of whether they stopped taking the drug.

The pill appears to be slightly more effective than Eli Lilly’s experimental oral drug, which has no dietary restrictions.

The petty and infantile purpose Trump will not permit Machado to steer Venezuela

Donald Trump is by far the pettiest president in US history. He never forgets an insult, even if most of them are imagined, and he seeks revenge against people he sees as political enemies.

We have often seen this behavior in action in the United States, as even after their deaths Trump will continue to mock and criticize people like John McCain, whose unforgivable sin in Trump’s eyes was voting against repeal of the Affordable Care Act.

PoliticusUSA is not beholden to any particular interest or political party. We are 100% independent. Support us by becoming a subscriber.

Trump sought to launch revenge cases against those who had the courage to either speak out about potential wrongdoing in his first administration, like James Comey, or to successfully prosecute him, like New York State Attorney General Letitia James.

The courts have ensured that much of Trump’s agenda hits a wall, or at least faces obstacles, in the United States He has moved his pursuit of unlimited power and control overseas.

Venezuelan opposition leader María Corina Machado was widely expected to be the next president if Maduro was ever toppled from power. She was seen as the person who could usher in a new era of democracy in her home country.

Machado won’t get that chance because, according to new reports, she made the mistake of incurring Trump’s wrath He accepts the Nobel Peace Prize, which he covets.

Read more below.